脑部[18F]FDG PET对非典型帕金森综合征的诊断准确性
该回顾性研究纳入2017-2019年因怀疑非典型帕金森综合征(AP)而转诊行脑部[18F]FDG PET的156例患者,由对临床信息设盲但可获取多巴胺转运体显像的核医学专家判读,以随访6-72个月的临床诊断为参考标准。总体正确分类准确率为74%,对多系统萎缩(MSA)、路易体痴呆/帕金森病痴呆(DLB/PDD)和皮质基底节变性/进行性核上性麻痹(CBD/PSP)的敏感性与特异性分别为1.00与0.91、0.81与0.97、0.62与0.97。作者认为[18F]FDG PET可辅助AP的临床诊断。
要点
- 总体正确分类准确率为74%。
- MSA(n=20)敏感性1.00(95%CI 0.83-1.00),特异性0.91(95%CI 0.85-0.95)。
- DLB/PDD(n=26)敏感性0.81(95%CI 0.61-0.93),特异性0.97(95%CI 0.92-0.99)。
核心结论
- 研究结果支持额外使用[18F]FDG PET辅助非典型帕金森综合征的临床诊断,具有中等至高的敏感性和特异性。
- 使用[18F]FDG PET可能对患者的预后和支持性治疗有益,并可能对未来临床试验有用。
研究设计与样本
- 回顾性研究,纳入2017-2019年因怀疑非典型帕金森综合征而转诊行脑部[18F]FDG PET的156例患者。
- [18F]FDG PET由对临床信息设盲但可获取多巴胺转运体显像的核医学专家判读。
- 参考标准为随访6-72个月的临床诊断。
主要发现
- 总体正确分类准确率为74%。
- MSA(n=20)敏感性1.00(95%CI 0.83-1.00),特异性0.91(95%CI 0.85-0.95)。
- DLB/PDD(n=26)敏感性0.81(95%CI 0.61-0.93),特异性0.97(95%CI 0.92-0.99)。
- CBD/PSP(n=68)敏感性0.62(95%CI 0.49-0.73),特异性0.97(95%CI 0.90-0.99)。
关键数值与推荐
- 总体正确分类准确率为74%。
- MSA(n=20)敏感性1.00(95%CI 0.83-1.00),特异性0.91(95%CI 0.85-0.95)。
- DLB/PDD(n=26)敏感性0.81(95%CI 0.61-0.93),特异性0.97(95%CI 0.92-0.99)。
- CBD/PSP(n=68)敏感性0.62(95%CI 0.49-0.73),特异性0.97(95%CI 0.90-0.99)。
临床怎么用
- 作者认为[18F]FDG PET可辅助非典型帕金森综合征的临床诊断。
- 作者认为使用[18F]FDG PET可能对患者的预后和支持性治疗有益,并可能对未来临床试验有用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atypical parkinsonism (AP) often presents with Parkinson's symptoms but has a much worse long-term prognosis. The diagnosis is presently based on clinical criteria, but a cerebral positron emission tomography (PET) scan with [18F]fluoro-2-deoxy-2-D-glucose ([18F]FDG) may assist in the diagnosis of AP such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Lewy body dementia (DLB). Only few studies have evaluated the sensitivity and specificity of [18F]FDG PET for separating the diseases in a mixed patient population, which we aim to assess in a retrospective material. RESULTS: We identified 156 patients referred for a cerebral [18F]FDG PET for suspicion of AP during 2017-2019. The [18F]FDG PET was analysed by a nuclear medicine specialist blinded to clinical information but with access to dopamine transporter imaging. The reference standard was the follow-up clinical diagnosis (follow-up: 6-72 months). The overall accuracy for correct classification was 74%. Classification sensitivity (95% confidence interval, CI) and specificity (95% CI) for MSA (n = 20) were 1.00 (0.83-1.00) and 0.91 (0.85-0.95), for DLB/Parkinson with dementia (PDD) (n = 26) were 0.81 (0.61-0.93) and 0.97 (0.92-0.99) and for CBD/PSP (n = 68) were 0.62 (0.49-0.73) and 0.97 (0.90-0.99). CONCLUSIONS: Our results support the additional use of [18F]FDG PET for the clinical diagnosis of AP with moderate to high sensitivity and specificity. Use of [18F]FDG PET may be beneficial for prognosis and supportive treatment of the patients and useful for future clinical treatment trials.
引用
- Houssein NJ, Henriksen AC, Hejl AM, et al. Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism. EJNMMI Res. 2023. PMID: 37572162. doi:10.1186/s13550-023-01025-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。